Lamivudine increases hyperbilirubinemic risk in patients with severe hepatitis

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KIM, Sang Geon (Seoul National University, Seoul, Korea, Republic Of)
  • Co-author(s): Sang Geon Kim:
    Young Hee Choi: College of Pharmacy, Dongguk University, Korea, Republic Of
  • Abstract:


    US">A total of 1321 patients taking lamivudine alone or with others were evaluated using laboratory hits in an electronic medical system at Seoul National University Hospital from 2005 through 2011; the patients were grouped according to prior ALT: G#1 (normal), ALT<40 IU/L; G#2 (hepatitis), 40 IU/L ≤ ALT< 120 IU/L; G#3 (severe hepatitis),..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login